8-K: RxSight Announces Record Preliminary Q4 and Full-Year 2024 Results, Issues Strong 2025 Guidance

RxSight, Inc. reported preliminary unaudited fourth quarter and full-year 2024 financial results, exceeding initial revenue guidance and projecting continued growth for 2025.

Summary

• RxSight, Inc., an ophthalmic medical device company, announced preliminary unaudited financial results for Q4 and full-year 2024.
• Q4 2024 revenue is expected to be approximately $40.2 million, a 41% increase year-over-year.
• This growth was driven by the sale of 29,069 Light Adjustable Lenses (LAL/LAL+) and 83 Light Delivery Devices (LDDs).
• Full-year 2024 revenue is expected to reach approximately $139.9 million, marking a 57% increase compared to the prior year.
• The company sold 98,055 LALs and 305 LDDs in 2024.
• As of December 31, 2024, RxSight had an installed base of 971 LDDs, serving an estimated 15% of cataract surgeons in North America.
• LAL procedures now account for over 10% of the region's premium IOL market.
• The company's preliminary unaudited cash, cash equivalents, and short-term investments totaled $237.2 million at the end of 2024.
• RxSight provided 2025 revenue guidance in the range of $185.0 million to $197.0 million, representing 32% to 41% growth.
• The company projects a 2025 gross profit margin of 71% to 73% and operating expenses between $165.0 million and $170.0 million.

Sentiment

Score: 9

Explanation: The document expresses a very positive outlook with strong financial results, exceeding expectations, and ambitious growth plans.

Positives

• The company experienced significant revenue growth in both Q4 and full-year 2024.
• Procedure volume for LALs increased by 79% in 2024 compared to 2023.
• The installed base of LDDs grew by 46% in 2024.
• RxSight has a strong cash position with $237.2 million in cash, cash equivalents, and short-term investments.
• The company anticipates strong revenue growth and healthy gross profit margins in 2025.

Negatives

• The reported financial results are preliminary and unaudited, subject to change pending the completion of the 2024 audit.

Risks

• Actual results may differ materially from forward-looking statements due to various factors, including those described in the Company's SEC filings.
• The company faces competition in the ophthalmic medical device market.
• International expansion plans may face unforeseen challenges.
• The company's future success depends on continued innovation and adoption of its technology.

Future Outlook

RxSight anticipates strong adoption of its system in 2025, with revenue growth between 32% and 41%. The company plans to expand into international markets and continue innovating its technology.

Management Comments

• During the fourth quarter, we achieved record highs for LDD sales and LAL procedures, meaningfully exceeding our initial full-year 2024 revenue guidance.
• With nearly one thousand LDDs installed, we now serve an estimated 15% of cataract surgeons in North America, while LAL procedures account for over 10% of the regions premium IOL market.
• We believe this sustained growth in one of ophthalmologys most competitive segments reflects the growing recognition of the superior visual outcomes enabled by adjustability.
• In 2025, we expect adoption for the RxSight system to remain strong as we collaborate with a diverse range of customers to further expand the infrastructure for post-operative light treatments.
• Building on our momentum in North America, we also look forward to entering key international markets in Asia and Europe.
• Finally, leveraging the foundation established since our initial FDA approval, we plan to continue to innovate the RxSight system, that we believe will continue to set the standard for the premium IOL market for years to come.

Industry Context

RxSight is a player in the ophthalmic medical device industry, specifically focusing on the premium IOL market for cataract surgery. The company's technology competes with other premium IOL options and aims to differentiate itself through its post-operative adjustability.

Comparison to Industry Standards

• RxSight's LAL procedure volume represents over 10% of the premium IOL market in the regions served, indicating strong adoption compared to other premium IOL options. Specific comparable companies are not listed in the document.

Stakeholder Impact

• Shareholders may benefit from the company's strong financial performance and growth prospects.
• Employees may benefit from the company's expansion and continued investment in innovation.
• Customers (cataract surgeons) benefit from access to the RxSight technology, which offers customized vision solutions for patients.
• Patients benefit from improved visual outcomes after cataract surgery.

Next Steps

• Completion of the company's 2024 audit.
• Announcement of audited full-year 2024 and unaudited fourth quarter 2024 financial results in February 2025.
• Expansion into key international markets in Asia and Europe.
• Continued innovation of the RxSight system.

Key Dates